First trimester PAPP‐A in the detection of non‐Down syndrome aneuploidy
- 28 June 2001
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (7) , 547-549
- https://doi.org/10.1002/pd.105
Abstract
Combined first trimester screening using pregnancy associated plasma protein-A (PAPP-A), free β-human chorionic gonadotrophin, and nuchal translucency (NT), is currently accepted as probably the best combination for the detection of Down syndrome (DS). Current first trimester algorithms provide computed risks only for DS. However, low PAPP-A is also associated with other chromosome anomalies such as trisomy 13, 18, and sex chromosome aneuploidy. Thus, using currently available algorithms, some chromosome anomalies may not be detected. The purpose of the present study was to establish a low-end cut-off value for PAPP-A that would increase the detection rates for non-DS chromosome anomalies. The study included 1408 patients who underwent combined first trimester screening. To determine a low-end cut-off value for PAPP-A, a Receiver–Operator Characteristic (ROC) curve analysis was performed. In the entire study group there were 18 cases of chromosome anomalies (trisomy 21, 13, 18, sex chromosome anomalies), 14 of which were among screen-positive patients, a detection rate of 77.7% for all chromosome anomalies (95% CI: 55.7–99.7%). ROC curve analysis detected a statistically significant cut-off for PAPP-A at 0.25 MoM. If the definition of screen-positive were to also include patients with PAPP-A<0.25 MoM, the detection rate would increase to 88.8% for all chromosome anomalies (95% CI: 71.6–106%). This low cut-off value may be used until specific algorithms are implemented for non-Down syndrome aneuploidy. Copyright © 2001 John Wiley & Sons, Ltd.Keywords
This publication has 17 references indexed in Scilit:
- Screening for trisomy 13 by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 2000
- Combining Ultrasound and Biochemistry in First-Trimester Screening for Down's syndromePrenatal Diagnosis, 1997
- Gene expression of human pregnancy-associated plasma protein-A in placenta from trisomic pregnanciesPlacenta, 1996
- First trimester serum screening for down's syndromePrenatal Diagnosis, 1995
- Serum PAPP‐A and free β‐hCG are first‐trimester screening markers for down syndromePrenatal Diagnosis, 1994
- Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancyBJOG: An International Journal of Obstetrics and Gynaecology, 1994
- Maternal serum human chorionic gonadotrophin and pregnancy‐associated plasma protein a, markers for fetal down syndrome at 8–14 weeksPrenatal Diagnosis, 1994
- First‐trimester free beta (hCG) screening for Down syndromePrenatal Diagnosis, 1993
- Pregnancy-associated plasma protein A: A possible marker in the classification and prenatal diagnosis of Cornelia de Lange syndromePrenatal Diagnosis, 1983